Related Experiment Videos
[Clinical study of the action of dobutamine in acute cardiac insufficiency]
Insights
Dobutamine effectively treats severe heart failure, improving patient outcomes and hemodynamics. This study suggests clinical monitoring is sufficient, potentially broadening dobutamine use in heart failure patients.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Severe heart failure poses significant clinical challenges.
- Ischemic heart disease is a common comorbidity in heart failure patients.
Purpose:
- To evaluate the efficacy and safety of dobutamine in treating severe heart failure.
- To assess the need for invasive hemodynamic monitoring during dobutamine therapy.
Summary:
- 78 patients with severe heart failure received dobutamine, with 48 showing improvement.
- Dobutamine significantly increased blood pressure, cardiac index, and diuresis, while decreasing capillary pressure.
- Treatment tolerance was satisfactory, with no adverse effects on heart rate or ventricular excitability.
Impact:
- Dobutamine demonstrates value in managing severe heart failure, alone or with vasodilators.
- The study suggests dobutamine can be widely used with clinical monitoring, reducing the need for extensive hemodynamic assessment.
Abstract:
78 patients were treated with dobutamine for a severe episode of heart failure at a mean dose of 9.51 micrograms . kg-1 . min-1 for an average of 5 days. 59 of these patients had ischaemic heart disease, including 34 with recent infarcts. The monitoring of treatment was essentially clinical, consisting of repeated measurement of the heart rate, the systolic and diastolic blood pressure and the diuresis. A haemodynamic survey was performed in only 25 cases. 48 patients were improved. 24 of these patients had no clinical or radiological signs of heart failure at the end of the treatment. Dobutamine significantly increases the blood pressure (97.7 +/- 24.9 to 105.8 +/- 21 mm Hg), the diuresis and the cardiac index (2.02 +/- 0.51 to 2.52 +/- 0.54 l . min-1 . m-2) and it significantly decreases the mean capillary pressure (25.36 +/- 6.20 to 21.03 +/- 6.94 mm Hg). The tolerance was very satisfactory, particularly in terms of the heart rate, ventricular excitability and the progression of the coronary disease. This clinical study confirms the value of dobutamine in the treatment of severe heart failure, either alone or in combination with vasodilators. The authors do not believe tha haemodynamic monitoring is essential at the doses used, which means that dobutamine could be used more widely in these indications.